FIELD: biotechnology.
SUBSTANCE: invention relates to polypeptide conjugate with G-CSF activity including polypeptide with amino acid sequence which is differ from human hG-CSF sequence by 15 amino acid residues and is conjugated with 2-6 polyethylene glycol residues. Said conjugates have low in vitro biological activity, prolonged half-life in vivo, decreased receptor-mediated clearance.
EFFECT: accelerated stimulation of leukocyte and neutrophyl formation in contrast to non-conjugated recombinant human G-CSF.
16 cl, 11 dwg, 4 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| G-CSG CONJUGATES | 2001 |
|
RU2290411C2 |
| FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
| MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
| POLYPEPTIDES | 2011 |
|
RU2577964C2 |
| INTENSIFICATION OF ACTION OF ANTICANCER AGENTS | 2006 |
|
RU2422143C2 |
| POLYPEPTIDE CAPABLE OF OVERCOMING HEMATOENCEPHALIC BARRIER, AND CONJUGATE THEREOF | 2005 |
|
RU2408605C2 |
| APROTININ POLYPEPTIDES FOR TRANSPORT OF COMPOUND THROUGH BLOOD-BRAIN BARRIER | 2010 |
|
RU2611193C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| COMPOSITIONS AND METHODS OF USING FOR TREATING METABOLIC DISORDERS | 2014 |
|
RU2704285C2 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
